Bean, William B. 183
Bowman, Barbara H. 47
Costanzi, John J. 79
Engelhardt, H. Tristram, Jr. 139
Flewellen, Eugene H. 105
Nader, Philip R. 169
Nelson, Thomas E. 105
Quay, W. B. 87
Reynolds, Edward S. 55
Sordahl, L. A. 121
Willis, William D., Jr. 1

SUBJECT INDEX

Biochemical lesions 121
Biogenic amines 87
Biomedical and behavioral research 139
Cancer management 79
Cellular injury 55
Clinical investigator, problems and perils 183
Cystic fibrosis 47
Ethical principles in research 139
Mailgnant hyperthermia 105
Mucociliary inhibitor 47
Myocardial disease 121
Neuroendocrine systems 87
School health 169
Skeletal muscle lesion 105
Spinothalamic tract 1
University Medical Center 169

AUTHOR INDEX

Archer, L.T. 173

Benjamin, B. 173
Benumof, Jonathan L. 231
Bernanke, David H. 253, 278
Besch, H.R., Jr. 19
Borg, Thomas K. 321
Bugaisky, Lawrence 123

Caulfield, James B. 321
Crass, M.F., III 395, 439
Cutilletta, A.F. 95

Denslow, Stewart 305
Dowell, Russell T. 93, 139
Downing, S. Evans 157
Drummond, G.I. 37

Entman, Mark L. 53

Fiser, William P. 235
Fitzharris, Timothy P. 287, 305
Friday, Cheryl D. 235
Funderberg, Fiona M. 253

Haithcoat, Judith L. 139
Hasser, Eileen M. 139
Hess, Michael L. 193
Hinshaw, L.B. 173
Humphrey, Edward W. 223
Hutson, J.C. 387

Jones, L.R. 19

Kersten, Thomas E. 223
Kischer, C.W. 339, 357
Krause, Stephen M. 193

Lautsch, Elizabeth V. 371
Lefer, Allan M. 155, 209
LeRoy, E. Carwile 305

Markwald, Roger R. 249, 253, 278, 287

Peyton, M.D. 173

Read, Raymond C. 219, 235
Reddy, Y.S. 79
Rovetto, Michael J. 397

Shetlar, C.L. 339
Shetlar, Marvin R. 337, 339, 357
Shug, Austin L. 409
Sinclair-Smith, Bruce C. 429
Sordahl, Louis A. 3, 5
Stocco, D.M. 387

Thompson, Robert P. 287, 305
Tomanek, Robert J. 111

Van Winkle, W. Barry 53

Wyborny, Leigh E. 79

Zak, Radovan 123

SUBJECT INDEX

Abdominal aortic constriction 139-151
Acetyl
  CoA 397-407
  CoA/CoA ratio 409-428
Acetylcholine 53-78
Actin 79-90
  myosin 53-78
Acyl CoA 5-18
  fatty 397-407
  long-chain
    inhibition of adenine nucleotide translocator 409-428
    ratio of carnitine to 409-428
Adenine
  nucleotide translocator (ANT) 409-428
  translocase 5-18
Adenosine 397-407
  diphosphate, 5'- (ADP) 397-407
Adenylate cyclase 19-35, 53-78
Adventitia 287-407
Alamethicin 19-35
Alkalosis 397-407
Allopurinol 157-172
Alveolar hypoxia 223-230
Alveoli, airless 223-230
Ameroid plastic 339-356
AMP, cyclic 53-78
Anaerobic energy production 397-407
Anesthesia, one lung 235-245
Aneurysm(s) 305-319
  ventricular 321-333
Animal models 337-338
Anoxia 397-407
Aortic
  arch mesenchyme 287-304
  constriction, abdominal 139-151
Arterial blood pressure 321-333
Artery - See also Ischemia, -ic
  abdominal aortic constriction 139-151
  aortic arch mesenchyme 287-304
  arterial blood pressure 321-333
  conus arteriosus 249-251
  ductus arteriosus, patent 249-251
  truncus arteriosus 249-251, 287-304
  tunica media 287-304, 305-319
  veno-arterial shunt 235-245
Atelectasis 231-233
  effect of hemorrhagic shock on pulmonary shunt in 223-230
  in left lower lobe 223-230
  lobar 223-230
ATP 5-18, 397-407
ATPase
  activity
    azide-sensitive 19-35
    Na^+,K^+ 19-35
  Ca^{2+}-dependent 19-35
  myosin 53-78, 79-90
Atrioventricular (AV)
  canal 249-251, 253-270
  cushions 271-285
Atrium, -a 249-251, 321-333
A23187 19-35
Azide-sensitive ATPase activity 19-35

β - See Beta
Bacterial collagenase 305-319
Balloon cuff 339-356
Basal lamina 357-369
Basement membrane
  collagen 305-319
  diabetic microangiopathy 429-439
Beta
  adrenergic receptor(s) 19-35, 53-78
  aminopropionitrile 305-319, 321-333
  blocking 53-78
Binucleated cells 123-138
Blood - See also Ischemia, -ic
  flow
    decreased 231-233
    myocardial 397-407
    pulmonary 223-230
  hemodynamic studies 139-151
  pressure
    arterial 321-333
    coronary perfusion 157-172
  translocation of volume 223-230
  vessels 321-333
    diabetic microangiopathy 429-439
Bulbus cordis 253-270

Calcium 5-18
  flux 37-52

Calcium continued
pool 53-78
sarcolemmal pool 37-52
sarcolemmal transport 37-52
sarcoplasmic reticulum, contractile 37-52
transport 5-18, 53-78
Ca^{2+}
-dependent ATPase 19-35
-dependent phosphoprotein 19-35
efflux 19-35
oxalate 19-35
permeability 19-35
preloading 19-35
pump density 19-35
release, spontaneous 19-35
transport 19-35
uptake 19-35
Calsequestrin 19-35
Canine heart 397-407
and endotoxin 173-191
Capillaries 321-333
Carbohydrates 397-407
Cardiac - See also Heart
anomalies 271-285
autonomic function in shock 157-172
cell injury in shock 157-172
contractile proteins 193-207
contractility 53-78
cushion tissue 271-285
development 305-319
dynamics in shock 157-172
endocardial cushion tissue 287-304
enlargement, pressure-induced 139-151
failure in endotoxic shock 157-172
function in shock 173-191
histological changes in "irreversible" shock 157-172
hypertrophy
anemia 111-122
hyperthyroid state 111-122
long-term 111-122
pressure overload 111-122
regression 111-122
volume overload 111-122
jelly 249-251, 253-270, 271-285, 305-319
space 287-304
microsomes 19-35
muscle 19-35, 123-138, 321-333
myocytes 305-319
performance 157-172
skeleton 305-319
Cardiodepression 209-216
Cardiogenesis 249-251, 253-270
Carnitine
acetyl transferase (CAT) activity, increased 409-428
administration protected the ischemic myocardium 409-428
carrier system 429-439
fatty acyl- 397-407
long-chain acyl CoA ratio 409-428
loss of 409-428
Catecholamine(s) 53-78, 157-172, 397-407
depletion, myocardial 157-172
increased levels of 223-230
Cell(s)
binucleated 123-138
culture 271-285
cushion tissue 249-251, 253-270
differentiation 305-319
endothelial 357-369
injury in shock, cardiac 157-172
mesenchymal 271-285
muscle 139-151
myocyte 123-138, 321-333
cardiac 305-319
non-muscle 139-151
non-myocyte 123-138
pancreatic acinar 209-216
Cellular growth 123-138
Chick heart, embryonic 271-285
Chondroitin-4-sulfate 339-356
Chondroitin sulfate 249-251, 253-270, 271-285
Chromatin 95-109
Circulatory
adaptation, pulmonary 235-245
decreased blood flow 231-233
shock 209-216
CoASH 397-407
Collagen 249-251, 271-285, 305-319, 321-333, 357-369
cross-linking 321-333
type A 305-319
type B 305-319
type I 287-304, 305-319
type II 305-319
type III 305-319
type IV 287-304

Collagenase, bacterial 305-319
Compliance 321-333
Congenital heart disease 249-251
Connective tissue 249-251, 321-333. See also Collagen
  adventitia 287-304
  cardiac
    jelly 249-251, 253-270, 271-285
    skeleton 305-319
  elastin 287-304
  fibroblastic characteristics 387-391
  fibroblasts 321-333, 357-369
  mesenchyme 287-304
    cells 271-285
Contractile calcium sarcoplasmic reticulum 37-52
Conus arteriosus 249-251
Conus septum 287-304
Coronary perfusion pressure 157-172
Coupling ratios 19-35
Creatine
  phosphate 5-18, 397-407
  phosphokinase of mitochondrial membrane (CPK-MB) 5-18
Cushions, atrioventricular 271-285
Cushion tissue
  cardiac 271-285
  cells 249-251, 253-270
  endocardial 287-304
Cyclic
  AMP 53-78
  5'-AMP 397-407
  AMP-mediated phosphorylation 37-52
  GMP 53-78

Density gradient centrifugation 19-35
Depression of
  myocardial contractility 209-216
  reticuloendothelial system 209-216
Dermatan sulfate 339-356
Detergents 19-35
Diabetes
  ketoacidosis 429-439
  mellitus 429-439
  metabolic cardiomyopathy 429-439
  microangiopathy 429-439
6-diazo-5-oxo-L-norleucine (DON) 253-270
Digitalis 157-172
DNA 95-109
  synthesis 123-138
Dog hearts 397-407
Double-lumen endobronchial tube 235-245
Ductus arteriosus, patent 249-251

Early myocardial injury 371-386
E. coli endotoxemia 157-172
Elastin 287-304
Electrolyte-steroid 339-356
Electromagnetic flow meters 235-245
Electron microscopy 357-369
Electrophoresis 79-90
Endobronchial
  anesthesia 235-245
  double-lumen tube 235-245
Endocardial cushion tissue 287-304
Endocardium 253-270, 271-285, 287-304
Endothelial (cells) 357-369
Endotoxemia, E. coli 157-172
Endotoxin
  of canine heart 173-191
  myocardial response to 173-191
  shock and cardiac failure 157-172
  shock, role of heart in 173-191
Energy - See also Cyclic
  anaerobic production 397-407
  5'-ADP 397-407
  ATP 5-18, 397-407
  creatine phosphate 5-18, 397-407
  mitochondria 5-18, 111-122, 357-369
Enzymes 339-356. See also names of individual enzymes
Epinephrine 53-78
Excitation-contraction-coupling 193-207
Experimental myocardial infarction 339-356
Extracellular matrix 249-251, 253-270, 271-285, 305-319, 321-333

Fatty acid oxidation 397-407
Fatty acids 397-407
  free 439-452
Fatty acyl-carnitine 397-407
Fatty acyl CoA 397-407
Fibrin 357-369
Fibroblastic characteristics 387-391
Fibroblasts 321-333, 357-369
Fibronectin(s) 287-304, 321-333

Fibrous scar 371-386
Functional reserve capacity 139-151

Galactosamine 339-356
Ganglion stimulation, stellate 157-172
Gels, SDS-polyacrylamide 19-35
Globulin, cold insoluble 287-304
Glucosamine 253-270, 339-356
Glucose
  transport 397-407
  utilization 397-407
Glucose-6-phosphate 397-407
Glyceraldehyde-3-phosphate dehydrogenase 397-407
Glycocalyx 37-52
Glycogen 397-407
Glycogenolysis 53-78, 397-407
Glycolysis 397-407
Glycoprotein(s) 249-251, 253-270, 271-285, 287-304
Glycosaminoglycan(s) 249-251, 253-270, 271-285, 337-338, 339-356, 357-369
Glycosaminoglycan/proteoglycan 287-304
GMP, cyclic 53-78

Heart - See also Cardiac
  abdominal aortic constriction 139-151
  aneurysm 305-319, 321-333
  aortic arch mesenchyme 287-304
  arterial blood pressure 321-333
  atrioventricular
    canal 249-251, 253-270
    cushions 271-285
  atrium, -a 249-251, 321-333
  blood vessels 321-333
  bulbus cordis 253-270
  canine 173-191, 397-407
  chick, embryonic 271-285
  conus arteriosus 249-251
  conus septum 287-304
  coronary perfusion pressure 157-172
  coupling rates 19-35
  diabetic metabolic cardiomyopathy 429-439
  disease, congenital 249-251
  excitation-contraction-coupling 193-207
  myocardial infarction, experimental 339-356
  muscle function 139-151
  pig 397-407
  rat 397-407
  rate 321-333
  weight 339-356
Hemodynamic studies 139-151
Hemorrhagic shock 157-172, 209-216
  influences on pulmonary shunt in atelectasis 223-230
Heparan sulfate 253-270, 339-356
Heparin/heparan sulfate 249-251
Hexachlorotetrafluorobutane 339-356
Hexosamine 339-356
Hexoses 339-356
Histones 95-109
Humoral factor 387-391
Hyaluronate 249-251, 253-270, 271-285, 287-304
Hyaluronic acid 271-285, 339-356
Hydrogen ion 193-207, 397-407
N-2-hydroxyethylpiperazine-N'-2 ethanesulfonic acid (HEPES) 397-407
Hydroxyproline 339-356
Hyperglycemia 429-439
Hyperlipoproteinemia 429-439
Hyperplasia 139-151
Hypertension 321-333
Hypertrophic scar 357-369
Hypertrophy 5-18, 123-138, 139-151. See also Cardiac
  myocardial 95-109
  myofibrils 111-122
  T-tubules 111-122
  ultrastructure and quantitative aspects 111-122
  in young rats 123-138
Hypoxia 397-407
  alveolar 223-230
  pulmonary vascular response to 223-230
Hypoxic
  lung, models of 231-233
  pulmonary vasoconstriction 223-230, 231-233

Infarct, infarction
anatomic features 371-386
healing stages 371-386
interpretation of the clinical expressions 371-386
myocardial 337-338, 357-369, 387-391
experimental 339-356
healing 339-356
initial stages 371-386
Inotropic effect, positive 53-78
Intracellular pH 397-407
Ionophores 19-35
Ischemia 5-18, 397-407, 409-428
acute myocardial 439-452
local, effect on pulmonary shunt mechanism 223-230
Ischemic
areas 387-391
heart disease 321-333, 429-439
myocardium, protected by carnitine administration 409-428
Isoproterenol 53-78, 339-356, 397-407

Keloid formation 357-369
Kinase 53-78
light chain 79-90
myosin light chain 79-90
protein 53-78

Lactate 397-407
Lamina, basal 357-369
Light chain(s) 79-90
Light microscopy 371-386
Lobar atelectasis 223-230
Lobe, left lower 231-233
atelectasis 223-230
Long-chain acyl CoA
carnitine ratio 409-428
inhibition of adenine nucleotide translocator (ANT) 409-428
Lung
anesthesia, one lung 235-245
atelectatic 223-230, 231-233
cancer 235-245
hypoxic, models of 231-233
Lysosomal proteases 209-216
Lysosomes 193-207
Lysyl oxidase 321-333

Mean arterial blood pressure 321-333
Membrane
collagen, basement 305-319
diabetic microangiopathy 429-439
vesicles 19-35
Membranous septa 253-270
Mesenchymal cells 271-285
Mesenchyme, aortic arch 287-304
Metabolic acidosis 157-172
Methylprednisolone 223-230
Microangiopathy, diabetic 429-439
Microscopy
electron 357-369
light 371-386
Microsomal 53-78
Microsomes, cardiac 19-35
Microvascular occlusion 357-369
Mitochondria 5-18, 357-369
density 111-122
volume of cell 111-122
Monovalent cations 19-35
Morphological
alteration 371-386
characteristics 387-391
events, correlation and clinical significance of 371-386
Mucopolysaccharide 339-356. See also Glycosaminoglycan and individual listings
Muscarinic-cholinergic receptor 19-35
Muscle 19-35, 123-138, 139-151, 321-333. See also Myo
cardiac 19-35, 123-138, 321-333
diabetic metabolic cardiomyopathy 429-439
positive inotropic effect 53-78
skeletal 19-35, 321-333
smooth 321-333
Myocardial
anaerobic metabolism in shock 157-172
blood flow 397-407
catecholamine depletion 157-172
contractility 157-172
depressant factor 209-216
function 397-407
hypertrophy 95-109
infarction 337-338, 357-369, 387-391
chemical changes, weight 339-356
healing 339-356
initial stages 371-386
ischemia, acute 439-452
oxygen availability in shock 157-172
oxygen extraction and uptake 157-172
response to endotoxin 173-191

Myocardial continued
rupture 371-386
untrastructure in hemorrhagic shock 157-172
Myocardium 249-251, 253-270, 271-285
ventricular 305-319
Myocyte division 123-138
Myocytes 123-138, 321-333
cardiac 305-319
Myofibrils, normal growth and hypertrophy 111-122
Myofibroblasts 357-369
Myosin 79-90
actin- 79-90
ATPase 53-78, 79-90
light chain kinase 79-90

Na-Ca exchange sarcolemma purification 37-52
Na^+/Ca^{2+} exchange diffusion 19-35
Na^+,K^+-ATPase activity 19-35
Norepinephrine 157-172
N_2 ventilated-low ventilation/perfusion units 231-233
Nucleoproteins 95-109

Obesity 429-439
Outflow tract 305-319
Oxidation
enhanced pyruvate 409-428
fatty acid 397-407
Oxidative phosphorylation 5-18
Oxygen 5-18. See also Hypoxia, Mitochondria
anoxia 397-407
availability in shock 157-172
consumption 397-407
extraction and uptake 157-172

Palmitate 397-407
Pancreatic
acinar cell 209-216
hypoperfusion 209-216
pH, intracellular 397-407
Phosphodiesterase 53-78
Phosphofructokinase 397-407
Phospholamban 19-35, 53-78
Phospholipids 439-452
Phosphorylase 53-78, 397-407
Phosphorylated proteins 37-52
Phosphorylation 79-90
cyclic AMP-mediated 37-52
oxidative 5-18
Pig heart 397-407
Pneumothorax, surgical 235-245
Positive feedback loop 209-216
Positive inotropic 53-78
Premigratory matrix 253-270
Protein(s) - See also Collagen, Glycoproteins
actin 79-90
Ca^{2+}-dependent phosphoprotein 19-35
cardiac contractile 193-207
fibrin 357-369
globulin, cold insoluble 287-304
hyperlipoproteinemia 429-439
histones 95-109
kinase 53-78
myosin 53-78, 79-90
non-histone 95-109
nucleoproteins 95-109
phosphorylated 37-52
proteoglycan(s) 287-304
proteolysis 209-216
tropomyosin 53-78
troponin 53-78
Pulmonary
blood flow 223-230
circulatory adaptation 235-245
to acute atelectasis in man 235-245
shunt
fraction 223-230
mechanism, effect of local ischemia on 223-230
shunting following shock, increased 223-230
vascular
resistance in the atelectatic lung, increase in 223-230
response to hypoxia 223-230
vasculature, generalized tensing of the 223-230
vasoconstriction 235-245
Pyruvate
dehydrogenase 397-407
oxidation, enhanced 409-428

Radioactive (^{14}C) glycosamine uptake 339-356
Radioactive sulfate (^{35}S) uptake 339-356
Rat(s) 139-151, 397-407

Respiration 5-18
Reticuloendothelial (RE) system, depression of 209-216
RNA
  polymerase 95-109
  synthesis 95-109
Robertshaw double-lumen endobronchial catheter 235-245
Ryanodine 19-35

Sarcolemma 19-35, 37-52, 111-122, 193-207
Sarcolemmal 53-78
  calcium pool 37-52
  calcium transport 37-52
Sarcoplasmic reticulum 19-35, 53-78, 193-207
  glycogenolytic complex 53-78
Scar
  fibrous 371-386
  hypertrophic 357-369
  keloid formation 357-369
Semilunar valves 253-270, 305-319
Shock 193-207
  cardiac 157-172, 173-191
  circulatory 209-216
  endotoxin 173-191
  hemorrhagic 157-172, 209-216
  myocardial anaerobic metabolism in 157-172
Shunting mechanism 223-230
Sialic acid 19-35
Skeletal muscle 19-35, 321-333
Skeleton, cardiac 305-319
Sodium-calcium exchange sarcolemma purification 37-52
Sodium dodecyl sulfate (SDS)-polyacrylamide gels 19-35
Splanchnic
  mesoderm 287-304
  vasoconstriction 209-216
Stellate ganglion stimulation 157-172
Surgical pneumothorax 235-245
Styrene microsphere 339-356

Tension
  peak 53-78
    active 321-333
    passive 321-333
T-tubules, normal growth and hypertrophy 111-122
Thoracotomy 235-245
Tissue culture 387-391
Transcription 95-109
Translocation of blood volume 223-230
Transmural lipid metabolism 439-452
Triacylglycerol 439-452
Tropomyosin 53-78
Troponin 53-78
Truncal septation 305-319
Truncus arteriosus 249-251, 287-304
Tunica media 287-304, 305-319

Uronic acid 339-356

Valve(s)
  mitral 253-270
  semilunar 253-270, 305-319
  tricuspid 253-270
Vascular, vasculature
  microvascular occlusion 357-369
  pulmonary 223-230
  tone, increased 223-230
Vasoconstriction
  active 231-233
  pulmonary 235-245
    hypoxic 223-230, 231-233
  splanchnic 209-216
Veno-arterial shunt 235-245
Ventricle(s) 249-251, 305-319, 321-333
  conus arteriosus 249-251
  conus septum 287-304
  left 321-333
Ventricular
  aneurysms 321-333
  atrioventricular
    canal 249-251, 253-270
    cushions 271-285
  compliance 321-333
  failure 397-407
  function 157-172
    curves 157-172
  myocardium 305-319

Weanlings 123-138